Norepinephrine News and Research

RSS

Stress management can improve chronic skin conditions

As anyone with a chronic, inflammatory skin condition, such as psoriasis, rosacea or acne, knows, dealing with unpredictable flares can cause considerable stress and have a negative impact on a person's overall well-being.

4 Aug 2011

Artificial nanoparticles have direct effect on heart rate and rhythm

Artificial nanoparticles are becoming increasingly pervasive in modern life. However, their influence on our health and the mechanisms by which they affect the human body remain largely shrouded in mystery.

1 Aug 2011

Scientists reveal complete three-dimensional atomic structure of an activated GPCR

G protein-coupled receptors (GPCRs) are popular drug targets, accounting for about one-third of approved drugs and many hundreds of drugs currently in development. They act as molecular switches that transduce extracellular signals by activating heterotrimeric G proteins located at the inside of the cell.

27 Jul 2011

New antidepressant prescription linked to increased risk of falls in nursing home residents

Nursing home residents taking certain antidepressant medications are at an increased risk of falling in the days following the start of a new prescription or a dose increase of their current drug, according to a new study by the Institute for Aging Research of Hebrew SeniorLife, an affiliate of Harvard Medical School.

16 Jul 2011

PDF announces $1M for 11 novel Parkinson's research projects

The Parkinson's Disease Foundation (PDF) is pleased to announce awards totaling more than $1 million for 11 novel investigator-initiated research projects designed to understand the causes of and find a cure for Parkinson's disease.

8 Jul 2011

Novel neurotransmitter could fight against neurological diseases

A team of scientists has discovered that D-aspartic acid is a novel neurotransmitter that could potentially be used in the fight against neurological diseases such as Parkinson's and schizophrenia.

6 May 2011

Physical exercise generates nitric oxide intermediates critical for cardioprotection

Exercise both reduces the risk of a heart attack and protects the heart from injury if a heart attack does occur. For years, doctors have been trying to dissect how this second benefit of exercise works, with the aim of finding ways to protect the heart after a heart attack.

5 May 2011

Study: Dual medications do not hasten recovery from depression

Taking two medications for depression does not hasten recovery from the condition that affects 19 million Americans each year, researchers at UT Southwestern Medical Center have found in a national study.

3 May 2011

Research sheds light on molecular movements of neural transporters

A team of scientists from Columbia University College of Physicians and Surgeons and Weill Cornell Medical College has shed light on the molecular workings of transporter proteins, molecular machines embedded in the cell membranes of neurons that modulate the transfer of signals between cells and recycle neurotransmitters.

25 Apr 2011

America’s best loved drugs: Report

According to the latest report from consulting firm IMS Health, Americans are consuming a lot of prescription drugs. And they seem especially fond of those to lower their cholesterol, relieve heartburn, aid in depressive disorders and lessen pain. Overall, however, their spending on such drugs is slowing.

20 Apr 2011

Forest Labs fourth quarter net sales increase 9.7% to $1,091.9 million

Forest Laboratories, Inc., an international pharmaceutical manufacturer and marketer, announced that reported earnings per share equaled $1.12 in the fourth quarter of fiscal 2011.

19 Apr 2011

Investigational drug effective for patients with obesity

An investigational combination of drugs already approved to treat obesity, migraine and epilepsy produced up to a 10 percent weight loss in obese individuals participating in a one-year clinical trial, according to researchers at Duke University Medical Center.

11 Apr 2011

Persistent fatigue in breast cancer survivors may be caused by autonomic nervous system running in overdrive

The persistent fatigue that plagues one out of every three breast cancer survivors may be caused by one part of the autonomic nervous system running in overdrive, while the other part fails to slow it down.

7 Apr 2011

Study: Antidepressants can thicken arteries and lead to heart disease

Antidepressant use has been linked to thicker arteries, possibly contributing to the risk of heart disease and stroke, in a study of twin veterans. The data is being presented Tuesday, April 5 at the American College of Cardiology meeting in New Orleans.

4 Apr 2011

Antidepressants may increase heart attack or stroke risk in men: Study

...

3 Apr 2011

PHOENIX phase III trial of PHP for distributive shock to continue after positive midpoint recommendation from DMB

The PHOENIX trial is a European, placebo-controlled, Phase III study treating catecholamine-resistant patients in distributive shock with the Nitric Oxide (NO) scavenger Pyridoxalated Haemoglobin Polyoxyethylene Conjugate (PHP). The study was launched by Curacyte AG in Austria, Belgium, Germany, Spain, The Netherlands and in the United Kingdom in 2009.

28 Mar 2011

Cell receptor recycling mechanism discovery opens up new class of therapeutic targets

Prof. Manojkumar Puthenveedu of Carnegie Mellon University studies the mechanisms by which membrane trafficking controls and co-ordinates the complex signalling pathways in the brain. Despite the fact that almost all diseases can be traced to a defect in how cells respond to signals, little is known about how signalling pathways are maintained in normal cells and the changes that occur in abnormal conditions.

23 Mar 2011

New UCSD center investigates link between Alzheimer's and Down syndrome

A new center combining academic research with the treatment of adults with Down syndrome - one of the first in the country - has opened at the University of California, San Diego School of Medicine.

15 Mar 2011

Euthymics Bioscience initiates EB-1010 phase 2b/3a TRIADE clinical trial for major depressive disorder

Euthymics Bioscience, Inc. today announced the initiation of an advanced clinical study of its lead product candidate EB-1010 for the treatment of major depressive disorder (MDD). The TRIADE (Triple Reuptake Inhibitor Anti-Depressant Effects) trial is a phase 2b/3a clinical trial designed to assess the safety and efficacy of EB-1010, a novel serotonin-preferring triple reuptake inhibitor.

14 Mar 2011

Scientists suggest that lateral habenula can be a prime locus of human depression

A team of neuroscientists at Cold Spring Harbor Laboratory, Brookhaven National Laboratory and UC San Diego has collected evidence suggesting that a previously overlooked portion of the brain could be a prime locus of human depression.

24 Feb 2011